Drug testing services firm Inotiv's Q4 revenue beats estimates

Reuters12-04

Drug testing services firm Inotiv's Q4 revenue beats estimates

Overview

Inotiv Q4 FY 2025 revenue rose 5.9% to $138.1 mln, beating analyst expectations
Adjusted EBITDA for Q4 FY 2025 missed analyst estimates
Operating loss decreased 48.5% to $6.8 mln in Q4 FY 2025

Outlook

Company did not provide specific guidance for future periods

Result Drivers

DSA REVENUE GROWTH - Driven by increases in biotherapeutic analysis, general toxicology, and surgical services revenue
RMS COST REDUCTION - Reduction in costs related to non-human primates and depreciation improved RMS operating income
LEGAL SETTLEMENT BENEFIT - Legal settlement contributed to decreased operating expenses

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue	Beat	$138.1 mln	$135.61 mln (2 Analysts)
Q4 EPS		-$0.25
Q4 Net Income		-$8.60 mln
Q4 Adjusted EBITDA	Miss	$11.8 mln	$12.70 mln (2 Analysts)
Q4 Operating Income		-$6.80 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Inotiv Inc is $5.00, about 475% above its December 2 closing price of $0.87

Press Release: ID:nGNX8SbVd1

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588202452?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 05:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588202452","market":"nz","top_or_hot":-1,"title":"Drug testing services firm Inotiv's Q4 revenue beats estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Drug testing services firm Inotiv's Q4 revenue beats estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Inotiv Q4 FY 2025 revenue rose 5.9% to $138.1 mln, beating analyst expectations</p></li><li><p>Adjusted EBITDA for Q4 FY 2025 missed analyst estimates</p></li><li><p>Operating loss decreased 48.5% to $6.8 mln in Q4 FY 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company did not provide specific guidance for future periods</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>DSA REVENUE GROWTH - Driven by increases in biotherapeutic analysis, general toxicology, and surgical services revenue</p></li><li><p>RMS COST REDUCTION - Reduction in costs related to non-human primates and depreciation improved RMS operating income</p></li><li><p>LEGAL SETTLEMENT BENEFIT - Legal settlement contributed to decreased operating expenses</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>$138.1 mln</p></td><td><p>$135.61 mln (2 Analysts)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.25</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$8.60 mln</p></td><td></td></tr><tr><td><p>Q4 Adjusted EBITDA</p></td><td><p>Miss</p></td><td><p>$11.8 mln</p></td><td><p>$12.70 mln (2 Analysts)</p></td></tr><tr><td><p>Q4 Operating Income</p></td><td></td><td><p>-$6.80 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Inotiv Inc is $5.00, about 475% above its December 2 closing price of $0.87</p></li></ul><p>Press Release: <span>ID:nGNX8SbVd1</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Drug testing services firm Inotiv's Q4 revenue beats estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDrug testing services firm Inotiv's Q4 revenue beats estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-04 05:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Drug testing services firm Inotiv's Q4 revenue beats estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Inotiv Q4 FY 2025 revenue rose 5.9% to $138.1 mln, beating analyst expectations</p></li><li><p>Adjusted EBITDA for Q4 FY 2025 missed analyst estimates</p></li><li><p>Operating loss decreased 48.5% to $6.8 mln in Q4 FY 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company did not provide specific guidance for future periods</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>DSA REVENUE GROWTH - Driven by increases in biotherapeutic analysis, general toxicology, and surgical services revenue</p></li><li><p>RMS COST REDUCTION - Reduction in costs related to non-human primates and depreciation improved RMS operating income</p></li><li><p>LEGAL SETTLEMENT BENEFIT - Legal settlement contributed to decreased operating expenses</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>$138.1 mln</p></td><td><p>$135.61 mln (2 Analysts)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.25</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$8.60 mln</p></td><td></td></tr><tr><td><p>Q4 Adjusted EBITDA</p></td><td><p>Miss</p></td><td><p>$11.8 mln</p></td><td><p>$12.70 mln (2 Analysts)</p></td></tr><tr><td><p>Q4 Operating Income</p></td><td></td><td><p>-$6.80 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Inotiv Inc is $5.00, about 475% above its December 2 closing price of $0.87</p></li></ul><p>Press Release: <span>ID:nGNX8SbVd1</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NOTV","symbol_name":"Inotiv, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nL1N3X916U:1","article_id":"2588202452","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588202452","pubTimestamp":1764796895,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Drug testing services firm Inotiv's Q4 revenue beats estimatesOverviewInotiv Q4 FY 2025 revenue rose 5.9% to $138.1 mln, beating analyst expectationsAdjusted EBITDA for Q4 FY 2025 missed analyst estim","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NOTV":"Inotiv, Inc.","BK4121":"生命科学工具和服务"},"translate_title":"药物测试服务公司Inotiv第四季度收入超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NOTV":0.9},"content_text":"Drug testing services firm Inotiv's Q4 revenue beats estimatesOverviewInotiv Q4 FY 2025 revenue rose 5.9% to $138.1 mln, beating analyst expectationsAdjusted EBITDA for Q4 FY 2025 missed analyst estimatesOperating loss decreased 48.5% to $6.8 mln in Q4 FY 2025OutlookCompany did not provide specific guidance for future periodsResult DriversDSA REVENUE GROWTH - Driven by increases in biotherapeutic analysis, general toxicology, and surgical services revenueRMS COST REDUCTION - Reduction in costs related to non-human primates and depreciation improved RMS operating incomeLEGAL SETTLEMENT BENEFIT - Legal settlement contributed to decreased operating expensesKey DetailsMetricBeat/MissActualConsensus EstimateQ4 RevenueBeat$138.1 mln$135.61 mln (2 Analysts)Q4 EPS-$0.25Q4 Net Income-$8.60 mlnQ4 Adjusted EBITDAMiss$11.8 mln$12.70 mln (2 Analysts)Q4 Operating Income-$6.80 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Inotiv Inc is $5.00, about 475% above its December 2 closing price of $0.87Press Release: ID:nGNX8SbVd1For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588202452","isCrawlerRequest":true}